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Background: Fear of cancer recurrence (FCR) is common amongst cancer survivors.  There is rapidly 
growing research interest in FCR but a need to prioritise research to address the most pressing 
clinical issues and reduce duplication and fragmentation of effort. This study aimed to establish 
international consensus among clinical and academic FCR experts regarding priorities for FCR 
research.  
Methods: Members of the International Psycho-oncology Society (IPOS) Fear of Cancer Recurrence 
Special Interest Group (FORwards) were invited to participate in an online Delphi study. Research 
domains identified in Round 1 were presented and discussed at a focus group (Round 2) to 
consolidate the domains and items prior to presentation in further survey rounds (Round 3) aimed at 
gaining consensus on research priorities of international significance.  
Results: Thirty four research items were identified in Round 1 and 33 of the items were consolidated 
into 6 overarching themes through a focus group discussion with FCR experts. The 33 research items 
were presented in subsequent rounds of the delphi technique. Twenty one participants contributed 
to delphi round 1, 16 in round 2 and 25 and 29 participants for subsequent delphi rounds. Consensus 
was reached for 27 items in round 3.1. A further 4 research items were identified by panellists and 
included in round 3.2. After round 3.2, 35 individual research items were ratified by the panellists.  
Given the high levels of consensus and stability between rounds no further rounds were conducted. 
Overall intervention research was considered the most important focus for FCR research. Panellists 
identified models of care that facilitate greater access to FCR treatment and evaluation of the 
effectiveness of FCR interventions in real world settings as the two research items of highest priority. 
Defining the mechanisms of action and active components across FCR/P interventions, was the third 
highest priority identified.    
Conclusions: The findings of this study outline a research agenda for international FCR research. 
Intervention research to identify models of care that increase access to treatment, are based on a 
flexible approach based on symptom severity and can be delivered within routine clinical care, were 
identified as research areas to prioritise. Greater understanding of the active components and 
mechanisms of action of existing FCR interventions will facilitate increased tailoring of interventions 






Early diagnosis and improved treatments for cancer have led to higher survival rates.1 With 
improved survival there are increasing numbers of people living with the fear that their cancer will 
recur.2  New treatments have also led to increased numbers of people with advanced disease living 
with uncertainty. 3  While some degree of fear of recurrence (FCR) defined as ‘fear, worry or concern 
relating to the possibility that cancer will come back or progress’ 4(pg3267) is considered normal, nearly 
50% of survivors experience moderate to high levels, suggestive of clinical FCR. High levels of FCR 
can persist over time 5 and negatively impact psychological wellbeing and quality of life, resulting in 
increased utilization of healthcare resources.6-8 FCR is one of the most prevalent and severe unmet 
supportive care needs reported, with Simard et al reporting in their review that up to 79% of cancer 
survivors reporting FCR as an unmet need or concern. 6 
For these reasons, research interest in FCR has grown rapidly, evident from a doubling of the 
number of publications (based on a Pubmed  database search conducted June 2020) from a mean 
publication rate of 57 per year (2010- 2014) to 108 per year (2015-2020), including the publication of 
12 systematic reviews 2,5-7,10-17. These reviews summarise a broad range of research activity including 
identification of factors associated with FCR 5,13, FCR measurement7, FCR interventions and 
management 10,15,16, theoretical frameworks explaining FCR 14 and prevalence, determinants and 
consequences of FCR 6,11,12,17 as well as different care delivery models 18 and highlight that much of 
the research has been focused on FCR in breast cancer or mixed cancer samples composed mainly of 
colon, prostate, or lung and breast cancer patients.6 However despite the increasing volume of FCR 
research and progress made in areas such as FCR treatment, fundamental questions regarding 
assessment, optimal intervention across patient groups, and determinants of severity are still to be 
answered. 19 Establishing priorities for FCR research will increase the quality and clinical utility of 
findings, and reduce the potential for research waste through duplication and/or fragmentation of 
effort, and increased co-ordination of research will enhance funding competitiveness.20,21 
A recent priority-setting exercise for FCR research in Australia provided guidance for local research 
activities,22 however, these may not generalise more broadly given differences in settings delivering 
psycho-oncology care internationally. Similarly, although a review of ovarian cancer-specific 
psychosocial research gaps identified FCR as an important area for further research – the scope and 
focus of the FCR agenda for this patient group was not explored.23 Priority setting exercises have 
demonstrated their potential to inform research. For example, a 2-day FCR colloquium in Ottawa, 
Canada24 not only provided a consensus definition for FCR but also highlighted the need for research 
to standardise measurement and development of theoretically informed interventions. Fostered 
through the establishment of a Special Interest Group under the banner of the International Psycho-
Oncology Society (FORwards), these objectives have driven FCR research to date, but have now 
largely been met. In this study, we aimed to build on previous priority setting exercises and gain 
consensus on international FCR research priorities to foster collaborative research efforts and 





A mixed methods approach was adopted to identify research priorities based on the methodology 
used in previous priority setting activities.22 Round 1 of the Delphi to identify research domains of 
potential importance, involved completion of an online survey. The survey results were presented 
and discussed at a focus group (Round 2) to consolidate the domains identified in round 1 prior to 
presentation in further survey rounds aimed at gaining consensus on research priorities of 
international significance to guide future collaborative research. The Delphi technique is a research 
methodology for establishing consensus among experts through a series of questionnaires 25 and 
commonly used to identify research priorities. 21,22,26 
 
Participants 
Participants were recruited through the International Psycho-oncology Society (IPOS) fear of cancer 
recurrence special interest group (FORwards). IPOS is an international multidisciplinary professional 
network of researchers and clinicians (n=598 from 68 countries) established to foster clinical and 
research collaborations to support the psychosocial health of those affected by cancer. The 
FORwards special interest group is comprised of IPOS members with an interest in FCR (n=85 from 
23 countries). The broad aims of the group are to raise awareness of FCR and promote activities to 
improve the identification and treatment of high levels of FCR amongst cancer patients and the 
group has a strong focus on stimulating multi-disciplinary, international FCR research. FORwards 
members were emailed an invitation to participate in each phase of the Delphi, however for the 
focus group it was a requirement that members be present at the IPOS World Congress, Banff 
Canada, since this component required face to face participation and Banff represented an ideal 
opportunity when a large number of FCR experts were already present. . The study was approved by 
University of Sydney human ethics committee (HREC 2019/608).  
Data Collection  
Identification of Research Domains 
Round 1 
FORwards special interest group members were emailed an invitation to participate in round 1 of 
the Delphi,- an online survey. Interested participants provided online consent prior to accessing the 
survey. The survey was constructed and administered using RedCap (Research Electronic Data 
Capture) database, a secure, web-based software platform designed to support data capture for 
research studies.27 The descriptive survey asked respondents to indicate what they perceived to be 
the three most important FCR research priorities of international significance. Survey responses 
were collected as free text variables and content analysed using a conventional approach 28 by two 
researchers independently (JS and PB). Any disagreements were resolved through discussion to 
ensure consensus. The analysis identified a list of individual items, which were grouped into higher-
order themes to identify research domains. The individual items were weighted (score of 3 = first 
priority, 2 = second priority, 1 = third priority) and mean scores for each item were used to calculate 
an overall ranking of research priorities. 
Round 2 
The results of the survey were presented to FORwards members attending the IPOS World Congress 
in Banff Canada (September 2019) as part of a 90-minute focus group convened specifically to 
review and discuss FCR research priorities. An experienced qualitative researcher (JS) conducted the 
focus group and two researchers documented the discussion. The results of the content analysis 
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were presented to the focus group including each domain and associated items. The focus group 
followed a semi structured format with the facilitator guiding initial discussion and allowing 
participants to openly discuss potential research questions and priorities. All new research items 
generated through group discussion were included in the focus group transcript. Thematic analysis 29 
of participant responses was conducted by two researchers independently (JS and PB) and an agreed 
coding scheme developed, with subsequent higher-order analysis to identify overarching themes. 
The transcripts were reviewed line-by-line by a single author (JS) who searched for concepts, themes 
and ideas, and developed a preliminary coding scheme. Transcripts were read and coded by a 
second author independently (PB) who compared and discussed their individual coding choices. Any 
disagreements were resolved by discussion. The coding scheme was revised based on these 
discussions to develop a final coding structure. No a priori assumptions regarding priorities were 
made by the researchers. The researchers inductively developed two categories of descriptive 
themes from the data - the research priorities expressed by the participants and the rationale 
participants used to explain their research priorities. 
 
Gaining Consensus for Research Priorities 
Round 3 
Research items generated through the item identification phase were presented to FORwards 
members using an online Delphi consensus methodology.  Members were emailed an invitation to 
participate in an online consensus process and the survey was constructed and administered using 
RedCap. In each round, panellists indicated their agreement on the importance of each research 
item on a 5-point Likert scale (1= very important to 5 = not important at all). Panellists were able to 
provide free text comments explaining the reasons for their rating. Consensus was defined a-priori 
as 80 % or more of panellists rating the item either important / very important or not important/ not 
at all important.  Panellists were also able to indicate if there were other research priorities they 
perceived as important, but not included.  
Data from round 3.1 of the consensus process was summarised and any new items, as well as items 
where consensus was not reached (with percentages endorsing each response option and any free-
text responses), were re-presented in a second round (i.e. round 3.2).  We had an a priori stopping 
rule that no further rounds would be conducted when there were fewer than 2 items where 
consensus was achieved.  In round 3.2, panellists also nominated their top three research priorities, 
ranking them from 1 (most important) to 3 (3rd most important). Non-responders were e-mailed up 
to three reminders for each round.  
Statistical Analyses 
Data were exported from RedCap into an excel spreadsheet and analysed descriptively. Percentage 
agreement was calculated based on the number of respondents who agreed/ strongly agreed or 
disagreed/strongly disagreed on the importance an item, divided by the total number of 
respondents as a percentage. SPSS Statistics 24 (IBM, Armonk NY) was used to calculate mean 
importance for each item. Lower mean scores indicated higher perceived priority. From round 3.2 
data, the top 3 ranked research priorities from the total list of research items was calculated. The 
individual items were weighted (score of 1 = first priority, 2 = second priority, 3 = third priority) and 
total scores for each item were used to calculate an overall ranking.  Research domains were also 




3.1 Round One: Identification of Research Domains  
Twenty-one (25%) FORwards members completed the online survey. The majority of respondents 
were psychologists (66%, n=14), with >10 years working in oncology (71%, n=15). Sixty six percent 
(n=14) of respondents indicated research accounted for >50% of their time, and 81% (n=17) 
indicated they were currently involved in FCR research.  The survey elicited 34 individual research 
items across five higher order themes to identify research domains: (1) intervention research, (2) 
screening and measurement, (3) model and/or guideline development, (4) aetiology of FCR and (5) 
implementation research. The full list of research items and associated weighting is provided as a 
supplementary file.  
3.2 Round Two: Consolidation of Research Items 
Sixteen (19%) FORwards members (12 psychologists, 2 nurses and 2 psychology graduate students 
involved in FCR research) from 9 countries participated in the focus group. Thematic analysis of the 
focus group discussion transcript resulted in refinement and reconceptualization of the research 
items identified from the survey and consolidation of 34 items across six overarching research 
domains: (1) intervention models (n=8 items), (2) researching specific populations (n=7 items), (3) 
definitions and mechanisms of action for FCR (n=8 items), (4) description of FCR predictors and 
consequences (n=4 items), (5) detection and screening (n=3 items) and (6) implementation (n=4 
items). All 34 research items were presented as part of the Delphi process and are listed in Table 1.  
3.3 Round Three: Consensus for Research Items 
3.3.1 Participants 
Twenty five (29% response rate) (FORwards members participated in round 3.1 of the Delphi 
consensus survey and 29 (34%) participated in round 3.2. The mostly female (83%) respondents 
were representative of the disciplines and international regions engaged in FCR research and IPOS 
membership (Table 1). 
Insert Table 1 here 
3.3.2 Consensus Rating 
Thirty-three research items were initially presented to panellists and 27 of these reached consensus 
(ш 80% agreement). Panellists also identified 4 additional items in round 3.1, including two items 
conceptualised under an additional domain Uncertainty and avoidance. The items where consensus 
was not reached (n=7) and the additional 4 items were re-presented to panellists in round 3.2. 
Consensus was reached on 9 items. Two items failed to reach consensus: Explore the underlying 
similarities and differences between Fear of Cancer Recurrence (FCR) and Fear of Progression (FoP) 
(72.4% agreement) and Examine the effects of FCR/P on use of alternative therapies and their costs 
(69% agreement). Thus, these two items were eliminated. In summary, given the stability across 
rounds, 35 individual research items were ratified by the panellists and no further rounds were 
conducted. Table 2 lists individual items grouped by domain and final level of consensus for each 
item in ranking order.  
Insert Table 2 here 
Research Priorities Ranking 
The mean ranking of the 7 research domains is listed in Table 3. Lower mean score is indicative of 
higher ranking of importance. Although all the priorities and related items were deemed important, 
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Intervention models was identified as the highest priority (rank 3.04) and Uncertainty and Avoidance 
lowest (rank 5.04).  In line with the ranked research domains, when asked to indicate their top three 
research items in order of importance, participants nominated two research items related to 
intervention models - Develop and evaluate more accessible models and Evaluate the effectiveness 
of existing interventions in real world settings, followed by Define the mechanisms of action and 
identify the active components across FCR/P interventions as the research of highest priority. 
Individual research items listed by >10% of participants as one of their top 3 priorities are listed in 
Table 4. Of note, although the item Explore the underlying similarities and differences between Fear 
of Cancer Recurrence (FCR) and Fear of Progression (FoP) failed to gain consensus, 5 panellists 
ranked this item as their 2nd or 3rd most important research domain. 
Insert Table 3 here 
Insert Table 4 here 
Discussion 
Through the use of Delphi methods this study developed consensus among key clinical and research 
stakeholders regarding aspects of FCR research that should be prioritised in future international 
collaborations. Based on the overall ranking of overarching themes, development and evaluation of 
intervention models was considered the most important focus for FCR research. In line with this, 
stakeholders identified development and evaluation of models of care that facilitate greater access 
to FCR treatment and evaluation of the effectiveness of FCR interventions in real world settings as 
the two research questions of highest priority, with high levels of consensus (96% and 92% 
respectively). Stakeholders also highlighted the importance of further work related to defining the 
mechanisms of action and active components across FCR/P interventions, ranking this research as 
the third highest priority.    
The results of this priority setting exercise confirm that although the existing treatment protocols 
incorporating interventions delivered by specialist mental health clinicians are effective,16 there 
remains a need to evaluate new service delivery models aimed at increasing accessibility. 
Preliminary research investigating use of online delivery and oncologist and nursing-led 
interventions reflects this move to more accessible alternatives.18,30-33 The focus on flexible delivery 
options is not surprising given increasing international efforts directed toward survivorship care 
models better tailored to address the needs-support gap.34 For cancer survivors dealing with FCR, 
evidence-based models of care outside of the hospital-setting are perceived as a valid means of 
reducing the burden of distress experienced,30 although these interventions have yet to 
demonstrate their efficacy.35  
Given FCR treatment models are currently time and resource intensive, there was also clear support 
for evaluation of stepped care approaches incorporating interventions tailored to FCR severity, such 
that more intensive interventions (psychologist delivered face to face sessions) are reserved for 
patients with clinical levels of FCR who do not benefit from simpler first line approaches (online or 
non-mental health delivered). A stepped care approach is however contingent on the identification 
of clinical cut-offs to appropriately identify the intensity of intervention best suited to severity of 
symptoms experienced. The stepped care approach to anxiety and depression screening and 
management as outlined in the clinical pathway for identification and management of anxiety and 
depression in cancer36 provides a useful framework for the development of multi-disciplinary 
evidence-based guidance for FCR management. Although trials of evidence-based stepped care 
models have not yet been reported, a number of brief interventions among patients with low levels 
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of FCR and interventions aimed at FCR prevention hold promise for this approach. 37,38 Prevention of 
FCR was also highlighted as a key area for future research. Finally, stakeholders acknowledged that 
efficacy of FCR interventions has been confirmed under ideal settings within randomised controlled 
trials targeting early stage, primarily breast cancer patients 15 To facilitate greater translation of 
evidence into practice, they highlighted the need to conduct pragmatic trials, encompassing more 
diverse patient groups both in terms of disease and socio-demographic factors, conducted in routine 
clinical settings that reflect a diversity of cultural contexts, to ensure interventions are evaluated 
under real world conditions. 39  
Despite the dissemination of a number of FCR conceptual models  14,15,40-42 and exploration of 
relationships between FCR and related constructs (eg death anxiety 43, pain 44), stakeholders 
reported research to better understand the mechanisms of action and active components of FCR 
interventions as one of their top three priorities. A number of recent studies have reported 
moderators and mediators of FCR in terms of patient level characteristics 45,46 and mechanisms of 
treatment efficacy. 40,47 A meta-analysis of FCR interventions also found that more contemporary 
forms of CBT aimed at modifying thought processes (i.e. how individuals relate to their inner 
experiences, rather than thought contents) were more effective15. However, the link between 
cognitions and behaviours common in FCR, and individual intervention components, has not been 
established.  Conducting comparative effectiveness studies (ie head to head trials) between FCR 
interventions may also help to better understand the relative merits of different interventions.48 
Stakeholders confirmed such information would facilitate not only replication of findings, but also 
inform optimisation of existing interventions in terms of treatment dose and determining where 
active elements can be adapted or modified in real-world settings. 49  
Understanding the mechanisms of action can also help to predict who might best benefit from 
available treatments. Stakeholders questioned whether the differing prognostic outcomes of disease 
influence the FCR trajectory for individual patients in clinically meaningful ways. Ratings indicated 
that stakeholders perceived that exploring potential differences across prognostic categories will 
inform development of interventions that better target recurrence and progression fears across 
different patient groups.  
An interesting finding of this study which differs from the findings of the Australian Delphi study, 22 
was the support for greater research to explore the relationship between avoidance, uncertainty 
and FCR. Stakeholders noted that while current conceptualisations of FCR have focused on those 
cognitions that drive hypervigilance, less attention has been given to patients who engage in 
avoidant behaviours. This patient group was of particular concern to the stakeholders as the risk of 
recurrence was higher due to their avoidant health behaviours aimed at reducing fear and 
uncertainty.15 The role of uncertainty, which has previously been linked with increased FCR, 40 was 
also highlighted as an important area of research in light of newer immune and targeted therapies 
which offer uncertain futures to patients with advanced disease. 50 
Finally, it should be noted that two research topics proposed in the initial survey and confirmed 
during the focus group discussion failed to reach consensus. However both topics were conceptually 
similar to other items within the Delphi where consensus was reached; for example, the item explore 
the underlying similarities and differences between FCR and fear of progression (72.4% agreement) is 
closely related to a number of other items within the Definitions and Mechanisms of Action theme 
such as refining the definitions of FCR and FoP and the theoretical model that explains FCR/P both of 
which reached consensus (88%). Similarly, the item effects of FCR/P on use of alternative therapies 
and their costs (69% agreement) may have been subsumed into the broader item examine the 
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effects of FCR/P on healthcare seeking / health service utilisation and associated costs (96% 
agreement). 
The results of this consensus study need to be viewed in light of a number of limitations. Firstly, 
although all members of the FORwards special interest group were invited to participate at each 
phase of the research, overall participation rates were low with less than one third of members 
completing the Delphi study. Additionally, FORwards members are predominately from Western-
culture based and OECD nations, limiting potential  multicultural considerations of FCR research. 
Participation in the focus group was limited to only those FORwards members able to attend the 
IPOS World Congress. Despite the low recruitment rate, those who did participate represented key 
opinion leaders in the field and therefore were able to provide expert advice on the state of current 
international research. There was also there was limited representation of stakeholders from 
developing nations, although given the limited psycho-oncology services available, the findings 
around the need for increased FCR treatment accessibility may not have changed. A strength of this 
study was the international multidisciplinary participation, although there was an over-
representation of psychologists. However, given psychologists are the discipline most commonly 
treating FCR, their engagement with this agenda setting supports the clinical relevance of 
recommendations resulting from the consensus process. Finally, although the conduct of the Delphi 
was based on best practice methodologies, the majority of research items were rated highly, and 
once consensus was reached were not re-presented in subsequent rounds. Re-presenting items after 
consensus was reached may have provided greater differentiation of research priorities and better 
refined some of the lower ranked priorities. However, the high levels of consensus across a broad 
range of themes highlights the breadth of research questions yet to be answered. Given 
stakeholders were able to identify the three most important research topics to be addressed 
internationally and are largely consistent with the priorities identified by the Australian Delphi 
study,22 despite the study limitations, the findings confirm a clear direction to researchers and 
funding bodies about the nature of the research that should be considered in the immediate future. 
 
Conclusions 
The findings of this study provide a roadmap for international FCR research. Stakeholders confirmed 
intervention research to identify models of care that increase access to treatment, are based on a 
stepped care approach and are able to deliver as part of routine clinical care, as the highest priorities 
for future research. Greater understanding of the active components and mechanisms of action of 
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Table 1: Delphi Round 3 respondent characteristics 











Age 26-30 5 (20) 2 (7)  
 31-40 7 (28) 10 (36)  
 41-50 7 (28) 6 (21)  
 51-60 4 (16) 7 (25)  
 61-69 2 (8) 3 (11)  
 >70 0 (0) 0 (0)  
     
Gender Female 20 (80) 24 (82) 478 (80) 
 Male 5 (20) 5 (18) 120 (20) 
     
Discipline Psychology 14 (56) 17 (59) 244 (41) 
 Psychiatry 1 (4) 2 (7) 80 (13) 
 Nursing 1 (4) 2 (7) 40 (7) 
 Social work 0 (0) 0 (0) 14 (1) 
 Oncology 0 (0) 0 (0) 18(2) 
 Research 9 (36) 8 (27) 83 (14) 
     
Country * Australia 5 (20)  63 (11) 
 Canada 4 (16)  30(5) 
 Denmark 1 (4)  7 (1) 
 Japan 1 (4)  22 (4) 
 Mexico 1 (4)  11 (2) 
 Netherlands 3 (12)  11 (2) 
 Portugal 1 (4)  2 (0.3) 
 Russia 1 (4)  7 (1) 
 South Korea 1 (4)  4 (0.7) 
 Spain 2 (8)  3 (0.5) 
 United 
Kingdom 




3 (12)  93 (16) 
     
Research 
role 
Up to 5% 1 (4) 1 (3)  
 5%-10% 3 (12) 2 (7)  
 10%-15% 2 (8) 3 (11)  
 15%-25% 0 (0) 0 (0)  
 25%-50% 4 (16) 5 (17)  
 50%-75% 4 (16) 5 (17)  
 75%-100% 11(44) 13 (45)  
*due to a programming error country was not collected in round 2  





Table 2: Mean ratings and level of consensus for fear of cancer recurrence international research priorities 
Research Priority Round 3.1 Round 3.2 
Intervention Models Mean (SD)* % agreement(n) Mean (SD)* 
% agreement 
(n) 
Develop and evaluate more accessible models (low cost, online, 
telehealth, group, blended models of care, non-mental health delivered) 1.32 (0.56) 96 (25)   
Evaluate the effectiveness of existing interventions in real world settings 
(pragmatic trials) 
 
1.48 (0.77) 92 (25)   
Develop and evaluate brief FCR/P interventions (suitable for inpatients, 
single session interventions at follow up appointments) 
 
1.6 (0.71) 88 (25)   
Develop and evaluate stepped care interventions for low, sub-clinical, 
clinical levels of FCR/P 
 
1.56 (0.71) 88 (25)   
Develop and evaluate early interventions for prevention of FCR/P 
 1.64 (0.76) 84 (25)   
Develop international collaborations for FCR/P intervention studies and 
evaluate cross-cultural validity of interventions 
 
1.6 (0.87) 84 (25)   
Develop and evaluate interventions for sub-clinical levels of FCR/P 
 2.12 (0.78) 72 (25) 1.86 (0.74) 86 (29) 
Develop and evaluate FCR/P interventions delivered in community 
settings (non-cancer settings) 
 
1.92 (0.81) 72 (25) 1.79 (1.01) 86 (29) 
Reaching specific populations      
Explore FCR/P in 'avoidant' people (ie those people who manage FCR/P 
by avoiding health-related behaviours/follow up appointments) 
 
1.6 (0.65) 92 (25)   
Explore FCR/P in patients having new treatments (eg immunotherapy, 










Explore FCR/P in caregivers of people with cancer (parents or relatives of 
people with cancer) 
 
1.72 (0.84) 84 (25)   
Explore Fear of Progression (FoP) in patients with advanced disease (for 
whom existential issues are more relevant) 
 
1.76 (0.97) 80 (25)    








Explore the prevalence of FCR/P across cancer groups   2.2 (0.91) 56 (25) 1.66 (0.86) 90 (29) 
Explore how caregivers and people with cancer influence each other's 
FCR/P 
not yet 
defined  1.52 (0.69) 86 (29) 
Definitions and Mechanisms of Action     
       
Describe trajectories of FCR/P and identify covariates to explain any 
differences 
 
1.64 (0.64) 92 (25) 
  
Map interventions to the different FCR/P trajectories 
 
1.56 (0.65) 92 (25)   
Define the mechanisms of action and identify the active components 
across FCR/P interventions 
1.28 (0.61) 92 (25)   
Refine the definitions of FCR and FoP 172 (0.89) 88 (25)   
Refine the theoretical model that explains FCR/P 1.60 (0.82) 88 (25)   
Explore the relationship between FCR/P and healthy anxiety 1.76 (0.72) 84 (25)   
Explore the underlying similarities and differences between Fear of 
Cancer Recurrence (FCR) and Fear of Progression (FoP) 
1.88 (0.97) 76(25) 1.79 (1.01) 72 (29) 
Explore the relationship between FCR/P and tolerating uncertainty more 
generally 
1.76 (0.83) 72 (25) 1.31 (0.54) 96 (29) 
Description of FCR/P predictors and consequences        
Examine the effects of FCR/P on healthcare seeking / health service 




Establish predictors of clinically significant FCR/P 
 
 
1.48 (0.65) 92 (25)   
Establish predictive models for FCR/P 
 
 
1.60 (0.76) 84 (25)   




1.64 (0.81) 80 (25)   
Examine the effects of FCR/P on use of alternative therapies and their 
costs 
not yet 
defined  1.97 (0.98) 69 (29) 
Detection and Screening     
Develop better clinical and outcome measures of FCR/P which reflect 
clinical criteria for FCR/P 
 
1.44 (0.65) 92 (25)   
Develop better FCR/P screening measures which reflect clinical criteria 
for FCR/P 
 
1.36 (0.64) 92 (25)   
Establish clear clinical cut-offs for FCR/P screening measures (to guide 
intervention recommendations) 
 
1.52 (0.71) 88 (25)   
Implementation     
Develop FCR/P clinical guidelines 1.50 (0.66) 92 (24)   
Develop and evaluate implementation research outcomes for FCR/P 
interventions 1.52 (0.79) 83 (23)   
Conduct health economic analyses of FCR/P intervention 1.83 (0.92) 75 (24) 1.24 (0.44) 100 (29) 
Evaluate implementation of routine screening for FCR/P 1.78 (0.85) 74 (23) 1.24 (0.51) 97 (29) 
Uncertainty and avoidance     
Explore the relationship between uncertainty 
and FCR/P 
not yet 
defined  1.59 (0.73) 86 (29) 
In revi
ew
Explore the relationship between avoidance, 
uncertainty and FCR/P 
not yet 
defined  1.59 (0.78) 83 29) 
Mean of reported scores for each item where 1 = very important, to 5 = not at all important (possible range 1-5) 
In revi
ew
Table 3: Mean Rank of Overall Research Themes 




Definitions and Mechanisms of Action for FCR/P 3.25 
Detection and Screening 3.64 
Description of FCR/P predictors and 
consequences 4.00 
Implementation 4.36 
Reaching specific populations  4.68 
Uncertainty and Avoidance 5.04 















Develop and evaluate more accessible models – low 
cost, online, telehealth, group, blended models of 
care, non-mental health delivered (theme 1) 
6 3 5 14 (48%) 
Evaluate the effectiveness of existing interventions in 
real world settings (theme 1) 5 1 3 9 (31%) 
Define the mechanisms of action and identify the 
active components across FCR/P interventions (theme 
3) 
3 1 2 6 (20.6%) 
Explore the relationship between avoidance, 
uncertainty and FCR/P (theme 7) 3 0 2 5 (17.2%) 
Develop and evaluate stepped care interventions for 
low, sub-clinical, clinical levels of FCR/P (theme 1) 2 3 0 5 (17.2%) 
Explore the underlying similarities and differences 
between Fear of Cancer Recurrence (FCR) and Fear of 
Progression (FoP) (theme3) 
0 2 3 5 (17.2%) 
Explore FCR/P in patients having new treatments (e.g. 
immunotherapy, targeted therapy etc) on FCR/P 
(theme2) 
1 0 3 4 (13.8%) 
Develop and evaluate early interventions for 
prevention of FCR/P (theme1) 1 2 1 4 (13.8%) 
Refine the theoretical model that explains FCR/P 0 1 3 4 (13.8%) 
* only topics listed by >10% of participants are reported 
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